Guest Editor: Greg Russotti, Vice President, Technical Operations, Celgene Cellular Therapeutics
A perennially challenging area for cell therapy, product characterization/CMC has lately come to the fore as perhaps THE next critical manufacturing-related obstacle that must be properly addressed. Heavily funded consortia and renewed investment (from established tool providers and new faces on the cell therapy scene alike) are helping to drive technological innovation, regulatory guideline development and standardization efforts. But fundamental questions remain: which assays and solutions do you really need to employ? Whose product characterization standards should you meet? And what is the most cost-effective way to strengthen and accelerate Quality Control processes for novel cell therapies approaching commercialization?
- Recent evolution in product characterization tools (eg. flow cytometry, live cell imaging, single cell analysis)
- How to reduce the heavy burden of QC and release testing on production timelines and Cost of Goods?
- How are regulators’ expectations and requirements evolving as cell therapies continue to advance into the commercial sphere – for instance, in regard to potency and comparability?
- What is the state-of-the-art – and practical utility of – in-process analytics today?
GUEST EDITOR: Rob Piperno, Director Cell and Gene Therapy QA, GlaxoSmithKline
As the cell & gene therapy space continues to grow at a rate of knots, there is perhaps no greater bottleneck on the horizon than the supply of critical raw materials. Add in the hefty contribution they can make to overall Cost of Goods, plus a dizzying array of technological, practical, logistical, regulatory and educational challenges, and you have a potential minefield. However, materials producers/suppliers and manufacturers of both autologous and allogeneic cell & gene therapies are bringing novel innovations to the fore to ensure that raw and starting materials can be a vital source of insight, confidence and competitive advantage.
- Troubleshooting apheresis and leukapheresis processes and management
- Interrogating the predictability of raw and starting materials to inform subsequent bioprocessing
- Regulatory compliance and standardization
- Next-generation raw materials (serum-free media)
GUEST EDITOR: Alan Smith, Bellicum
Optimizing and automating scalable bioreactors and cell culture platforms for the reliable, high quality production of cells and viral vectors alike is an area of tremendous activity and innovation in cell & gene therapy. However, this is driven by a most pressing need to advance beyond current technological limitations in order to meet burgeoning demand and to better control manufacturing costs, timelines and quality.
- Towards stable vector production platforms
- Relative pros and cons of the latest automated upstream bioprocessing unit operations and all-in-one devices
- Insights into scale-up success factors
GUEST EDITOR: Professor R. Jude Samulski, University of North Carolina at Chapel Hill
The landmark approval of Spark Therapeutics’ Luxturna changed the landscape of gene therapy forever and brought many lingering and emerging issues into sharp relief – not least, the need for viral and non-viral vector manufacturing to advance to a stage where it is genuinely fit for commercial purpose. As the current capacity crunch intensifies, the onus is on efficiency in product development and manufacture as never before.
- Advances in gene therapy characterization and QC
- Keys to successfully validating vector bioprocesses
- Latest regulatory guidance
GUEST EDITOR: Dr Mark Lowdell, Dir. Cellular Therapeutics, UCL
With Novartis and Kite, busying themselves with the roll out of Kymriah and Yescarta, it is timely to examine the latest progress in addressing long-standing manufacturing and supply chain-related challenges facing the cellular immunotherapy field, particularly at clinical and commercial scales.
- Assessing the latest strategic and technical solutions for autologous cellular immunotherapy product development and scalable manufacture (including automation technology)
- Next-generation CAR-T platforms, TCRs & combination approaches and enabling technologies
- Focus on the convergence of immuno-oncology and gene editing
- Progressing allogeneic cancer immunotherapy
GUEST EDITOR: Dr Christiane Niederlaender, Senior Quality Assessor, Biologicals, MHRA
The past few years have witnessed an unprecedented increase in the range of expedited regulatory pathways potentially available to cell & gene therapy developers across the world. From RMAT to PRIME, and from Breakthrough Designation to the PMD Act, a weight of experience and insight now exists to help you capitalize on the benefits whilst avoiding the pitfalls.
- Strategic pros/cons and practical considerations with accelerated development and conditional approval pathways
- Keys to remaining nimble and flexible with clinical trial designs and parallel product/process development
- Step-by-step guides to making successful pathway applications
GUEST EDITOR: Carlos R. Plata-Salamán, CSO, CMO and Head of R&D, Esteve
The application of novel animal models, cutting edge in vitro
and in silico
tools and innovation in the biomarkers realm all hold the potential to drive cell & gene therapy product candidates into First-in-Human trials. But how are regulators’ requirements evolving as the field and its technologies mature? And which tools and techniques will deliver the clinical insights critical to longer term success?
- Current and likely future preclinical requirements for established and emerging cell & gene therapy modalities
- Accelerating toxicology studies
- Addressing the need for predictive tools in immunotherapy
GUEST EDITOR: Lee Buckler, President & CEO, RepliCel Life Sciences Inc
Recent product approvals have only increased the sense of urgency to find viable pricing and reimbursement models for cell & gene therapies. They have also brought into sharper focus the need to educate and work with a wide variety of healthcare sector stakeholders – and of course, patients themselves - to ensure society benefits fully from such novel, disruptive therapeutic technologies.
COMING IN AUGUST 2019
- Evaluating the suitability of evolving P+R models
- Dissecting the market and patient access approaches of cell & gene therapy sector leaders
- Multiple stakeholder engagement strategies
GUEST EDITOR: Michael Covington, Principal, CMC Regulatory Policy & Strategy, Juno Therapeutics
As the need for rapid, robust and cost-effective downstream processing of cell & gene therapies has increased, so the sector’s enabling technology providers and their industrial and academic partners have invested and collaborated as never before to develop novel solutions, repurpose existing ones, and to seek clarity in regulatory guidelines and standards. Understanding exactly what benefits and advantages emerging options can offer – for example, automated and single-use tools – has never been more vital.
COMING IN SEPTEMBER 2019
- Product purification and polishing (of both cell-based therapies and viral vectors)
- Fill & finish and preparation for biopreservation
- Release testing
GUEST EDITOR: Dr Nicholas Medcalf, Head of Advanced Therapies and Enabling Programmes, Ageing Society, Health and Nutrition Directorate, UK Research and Innovation
Does decentralized manufacturing represent the future for commercial autologous cell & gene therapy products, and if so, where will it sit on a spectrum that stretches from regional facilities to the patient’s bedside itself? The potential benefits are manifold, but imposing challenges remain – not least the issue of regulatory oversight and QC the closer one gets to the point of care. However, the will and, increasingly, the technological solutions are emerging to make this a reality.
COMING IN OCTOBER 2019
- Making the business case for decentralized manufacturing
- The role of automation in enabling local and point of care bioprocessing
- Defining fit-for-purpose regulatory compliance models
GUEST EDITOR: Dr Timothy Miller, President & CEO, Abeona Therapeutics
The dramatic recent growth of a dedicated clinical tools and services sector signals both the rapid maturation of the advanced therapies space, and a growing awareness that specific, fit-for-purpose clinical trial protocols are needed to cater for the nuances of this field with its widely varying component technology platforms and target indications.
COMING IN NOVEMBER 2019
- Clinical trial protocols to prepare patients for in vivo and ex vivo gene therapy
- Blueprints for clinical operations and patient recruitment success
- Utility of adaptive trial designs in cell & gene therapy
GUEST EDITOR: TBA
Exploring the promise of synthetic biology in the cancer immunotherapy space in particular, this special edition will focus on enabling technologies at the bleeding edge with the potential to boost both safety and efficacy.
COMING IN NOVEMBER 2019
- Gene editing
- On/off switches to control T cell activation
With 2019 set to break yet more new ground in terms of commercial advances, translational and clinical R&D progress and platform technology innovation, the Twenty-Tens will surely go down as the most significant decade to date for the cell & gene therapy field.
This month, CGTI reviews and celebrates remarkable recent progress, and previews a new year and decade through analysis of 2019’s major trends and talking points – what will the Twenties hold in store for cell & gene therapy?
- KOL insights, reflections and horizon-gazing – just how far have we come and where do we go next?
- What were the most significant advances and issues of 2019 in terms of providing pointers to the future?
- Identifying both the key short-, mid- and longer-term challenges facing the global cell & gene therapy sector and next steps to their resolution. (Commercialisation, finance, manufacturing, R&D, regulation)
- Geographical analysis – how is the world of cell & gene therapy likely to evolve?
COMING IN DECEMBER 2019